USPTO 2015–2025 USPTO PatentsView US Corporation

AMO Development, LLC

USPTO PatentsView assignee record - 283 granted patents across 24 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

RSS updates for this company

The verdict

According to USPTO PatentsView, AMO ranks #1,468 of 49,997 tracked US assignees by granted-patent volume, with 283 patents across 24 technology areas.

#1,468
of 49,997 US assignees by volume
Top 9%
by Innovation Score (53.0/100)
14.0
avg claims per patent
+229%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R1468 · US Corporation #1,468 · 283 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-MID 283 grants
  • TOP-DECILE #1,468/49,997
  • PHOTO-FINISH Ab Initio Technology
  • CPC-FOCUS A61F · 24 areas
  • INNOV-PAR 53.0/100
  • CLAIMS-RICH 14.0 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-SURGE +229% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Ab Initio Technology LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around AMO

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows AMO's Innovation Score is 53.0/100 (top 9% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where AMO's grants concentrate

AMO Development, LLC is a focused PatentsView assignee: 24 CPC subclasses with 90.1% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2020 (52 grants) versus a trough of 7 in 2018. By volume, AMO sits between Sivantos Pte. Ltd. and Atieva, Inc..

AMO's three-year grant acceleration

From 2019–2021 to 2022–2024, AMO Development, LLC moved from 101 to 117 grants (1.16x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #854. See the growth leaderboard.

Who files at AMO's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows AMO holds 283 patents at rank #1,467, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near AMO

By rank, the assignees closest to #1,467 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in AMO's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for AMO, neither rank-band nor same-CPC leaders (those blocks stay above).

AMO's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

53 Top 9% higher than 91% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0102030405060 20152016201720182019202020212022202320242025 17
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
AMO Development, LLC patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 10 3.5%
2016 16 5.7%
2017 15 5.3%
2018 7 2.5%
2019 14 4.9%
2020 52 18.4%
2021 35 12.4%
2022 31 11.0%
2023 40 14.1%
2024 46 16.3%
2025partial year 17 6.0%

Which technologies does AMO Development, LLC patent most?

Top 15 of 24 technology areas

Where it ranks

Overall rank by patents

#1,468

of 49,997 tracked assignees

Innovation Score

53.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

AMO Development, LLC's patent record in context - here's where to go next.

  • AMO Development, LLC's lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 90.1% of its portfolio - see every assignee active in that class. Explore A61F
  • Ranked #1,468 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare AMO Development, LLC against Sivantos Pte. Ltd., an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 53.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.